- Aug 20, 2021
NCT05014646: Phase 2: Leflunomide for High-Risk Smoldering MM in African-Am. & European-Am. Patients
NCT05014646: Phase 2: Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American...
175
- Aug 20, 2021
NCT05014412: Phase 1/2: Elranatamab in MM That Has Come Back or Has not responded - MagnetisMM-9
MagnetisMM-9 NCT05014412: Phase 1/2: A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That...
309
- Aug 12, 2021
NCT04764942: Phase 1/2: Selinexor, Pom, Dex +/- Carfilzomib RRMM Multiple Myeloma, The SCOPE Trial
NCT04764942: Phase 1/2: Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With...
142
- Aug 7, 2021
NCT04816526: Phase 2 - Descartes-08 anti-BCMA-CAR-mRNA-transf. auto CD8+ T cells Consolidation MRD+
NCT04816526: Phase 2 - Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After...
210
- Aug 7, 2021
NCT04910568: Phase 1b - Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma...
818
- Aug 7, 2021
NCT04973605: Phase 1/2: BGB-11417 in Monotherapy and With Carfilzomib-dex in RRMM and t(11;14)
NCT04973605: Phase 1/2: A Phase 1b/2 Study of BGB-11417 in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in...
58